• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

SLC6A2 Gene Record

  • Summary
  • Interactions
  • Claims
  • SLC6A2 6530 Druggable Genome

    Alternate Names:

    6530
    SOLUTE CARRIER FAMILY 6 MEMBER 2
    SLC6A2
    NAT1
    NET
    NET1
    SLC6A5
    163970
    11048
    ENSG00000103546
    OTTHUMG00000133208
    P23975
    SC6A2_HUMAN
    PA310
    SODIUM-DEPENDENT NORADRENALINE TRANSPORTER (NOREPINEPHRINE TRANSPORTER) (NET). [SOURCE:UNIPROT/SWISSPROT;ACC:P23975]
    SODIUM-DEPENDENT NORADRENALINE TRANSPORTER
    Norepinephrine transporter
    SLCA2

    Gene Info:

    Human Readable Name DRUGGABLE GENOME
    Target Subclass Other
    Target Subclass SLC
    Target Subclass SLC6
    Target Main Class Transporters
    Transmembrane Helix Count 12
    Interpro Short Name Na/ntran_symport
    Interpro Acc IPR000175
    Uniprot Status Swiss-Prot
    Interpro Name Sodium:neurotransmitter symporter
    Human Readable Name TRANSPORTER
    Interpro Type Family
    Uniprot Evidence 1: Evidence at protein level
    Target Class Transporters
    Target Subclass TC:2.A.22.1.2
    Gene Biotype PROTEIN_CODING
    (7 More Sources)

    Gene Categories: Category Details

    TRANSPORTER
    CELL SURFACE
    DRUGGABLE GENOME

    Publications:

    Arias et al., 2009, Pharmacological and neurotoxicological actions mediated by bupropion and diethylpropion., Int. Rev. Neurobiol.
    Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
    Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
    Saba et al., 2007, [11C]LBT-999: a suitable radioligand for investigation of extra-striatal dopamine transporter with PET., Synapse
    Arai et al., 2003, Chronic inhibition of the norepinephrine transporter in the brain participates in seizure sensitization to cocaine and local anesthetics., Brain Res.
    Cloonan et al., 2010, The antidepressants maprotiline and fluoxetine have potent selective antiproliferative effects against Burkitt lymphoma independently of the norepinephrine and serotonin transporters., Leuk. Lymphoma
    Dronjak et al., 2007, Effects of noradrenaline and serotonin reuptake inhibitors on pituitary-adrenocortical and sympatho-adrenomedullar system of adult rats., Neuro Endocrinol. Lett.
    Mochizucki, 2004, Serotonin and noradrenaline reuptake inhibitors in animal models of pain., Hum Psychopharmacol
    Sagata et al., 2002, Tramadol inhibits norepinephrine transporter function at desipramine-binding sites in cultured bovine adrenal medullary cells., Anesth. Analg.
    Frink et al., 1996, Influence of tramadol on neurotransmitter systems of the rat brain., Arzneimittelforschung
    Berrocoso et al., 2009, Cooperative opioid and serotonergic mechanisms generate superior antidepressant-like effects in a mice model of depression., Int. J. Neuropsychopharmacol.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Barakat A, 2019, Revisiting Tramadol: A Multi-Modal Agent for Pain Management., CNS Drugs
    Garnock-Jones et al., 2009, Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents., Paediatr Drugs
    Biederman et al., 2002, Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/hyperactivity disorder., Pediatrics
    Michelson et al., 2003, Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies., Biol. Psychiatry
    Spencer et al., 2002, Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder., J Clin Psychiatry
    Wernicke et al., 2003, Cardiovascular effects of atomoxetine in children, adolescents, and adults., Drug Saf
    Tatsumi et al., 1997, Pharmacological profile of antidepressants and related compounds at human monoamine transporters., Eur. J. Pharmacol.
    Kaplan et al., 2004, Efficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder., J Atten Disord
    Wernicke et al., 2004, Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: a prospective, placebo-controlled assessment., J Clin Psychopharmacol
    Purper-Ouakil et al., [Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents]., Encephale
    Gaillez et al., 2007, [Atomoxetine (Strattera), an alternative in the treatment of attention-deficit/hyperactivity disorder (ADHD) in children]., Encephale
    Yang L et al., 2013, Adrenergic neurotransmitter system transporter and receptor genes associated with atomoxetine response in attention-deficit hyperactivity disorder children., J Neural Transm (Vienna)
    Ramoz N et al., 2009, A haplotype of the norepinephrine transporter (Net) gene Slc6a2 is associated with clinical response to atomoxetine in attention-deficit hyperactivity disorder (ADHD)., Neuropsychopharmacology
    Yu G et al., 2016, Atomoxetine: A Review of Its Pharmacokinetics and Pharmacogenomics Relative to Drug Disposition., J Child Adolesc Psychopharmacol
    Zhao et al., Perinatal cocaine exposure reduces myocardial norepinephrine transporter function in the neonatal rat., Neurotoxicol Teratol
    Carrera et al., 2004, Cocaine pharmacology and current pharmacotherapies for its abuse., Bioorg. Med. Chem.
    Burchett et al., 1997, Serotonin, dopamine and norepinephrine transporter mRNAs: heterogeneity of distribution and response to 'binge' cocaine administration., Brain Res. Mol. Brain Res.
    Galli et al., 1995, Sodium-dependent norepinephrine-induced currents in norepinephrine-transporter-transfected HEK-293 cells blocked by cocaine and antidepressants., J. Exp. Biol.
    Kantor et al., 2001, Protein kinase C and intracellular calcium are required for amphetamine-mediated dopamine release via the norepinephrine transporter in undifferentiated PC12 cells., J. Pharmacol. Exp. Ther.
    Tatsumi et al., 1999, Pharmacological profile of neuroleptics at human monoamine transporters., Eur. J. Pharmacol.
    Anton et al., 2004, Use of the norepinephrine transporter as a reporter gene for non-invasive imaging of genetically modified cells., J Gene Med
    Dziedzicka-Wasylewska et al., 2006, Effect of antidepressant drugs in mice lacking the norepinephrine transporter., Neuropsychopharmacology
    Mitchell et al., 2006, The effects of norepinephrine transporter inactivation on locomotor activity in mice., Biol. Psychiatry
    Haenisch B et al., 2011, Inhibitory potencies of trimipramine and its main metabolites at human monoamine and organic cation transporters., Psychopharmacology (Berl)
    Stahl et al., 2004, A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor., Prim Care Companion J Clin Psychiatry
    Bondarev et al., 2003, Behavioral and biochemical investigations of bupropion metabolites., Eur. J. Pharmacol.
    Shalabi AR et al., 2017, Deconstructed Analogues of Bupropion Reveal Structural Requirements for Transporter Inhibition versus Substrate-Induced Neurotransmitter Release., ACS Chem Neurosci
    Mortensen OV et al., 2006, Gain of function mutants reveal sites important for the interaction of the atypical inhibitors benztropine and bupropion with monoamine transporters., J Neurochem
    Jungkun et al., 2001, Long-term effects of tricyclic antidepressants on norepinephrine kinetics in humans., J Neural Transm (Vienna)
    Galli et al., 1996, Norepinephrine transporters have channel modes of conduction., Proc. Natl. Acad. Sci. U.S.A.
    Joyce et al., 2001, Interaction of local anaesthetic agents with the endogenous norepinephrine transporter in SH-SY5Y human neuroblastoma cells., Neurosci. Lett.
    Yi et al., 2005, Alpha-adrenergic modulation of synaptic transmission in rabbit pancreatic ganglia., Auton Neurosci
    Barker et al., 1996, Identification of a single amino acid, phenylalanine 586, that is responsible for high affinity interactions of tricyclic antidepressants with the human serotonin transporter., Mol. Pharmacol.
    Roubert et al., 2001, A Na(+)/Cl(-)-dependent transporter for catecholamines, identified as a norepinephrine transporter, is expressed in the brain of the teleost fish medaka (Oryzias latipes)., Mol. Pharmacol.
    Roubert et al., 2001, Determination of residues in the norepinephrine transporter that are critical for tricyclic antidepressant affinity., J. Biol. Chem.
    Vaishnavi et al., 2004, Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity., Biol. Psychiatry
    Kim et al., 2006, Monoamine transporter gene polymorphisms and antidepressant response in koreans with late-life depression., JAMA
    Reddy et al., 2010, Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician., Curr Med Res Opin
    Liebowitz et al., 2010, Efficacy, safety, and tolerability of Desvenlafaxine 50 mg/d for the treatment of major depressive disorder:a systematic review of clinical trials., Prim Care Companion J Clin Psychiatry
    Perry et al., 2009, Desvenlafaxine: a new serotonin-norepinephrine reuptake inhibitor for the treatment of adults with major depressive disorder., Clin Ther
    Mason et al., 2007, Desvenlafaxine succinate identifies novel antagonist binding determinants in the human norepinephrine transporter., J. Pharmacol. Exp. Ther.
    Deecher et al., 2006, Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor., J. Pharmacol. Exp. Ther.
    Kamath et al., 2008, Desvenlafaxine succinate for major depressive disorder: a critical review of the evidence., Expert Rev Neurother
    Angyal N et al., 2018, Association analysis of norepinephrine transporter polymorphisms and methylphenidate response in ADHD patients., Prog Neuropsychopharmacol Biol Psychiatry
    Myer NM et al., 2018, Pharmacogenetics predictors of methylphenidate efficacy in childhood ADHD., Mol Psychiatry
    Kim BN et al., 2013, Norepinephrine genes predict response time variability and methylphenidate-induced changes in neuropsychological function in attention deficit hyperactivity disorder., J Clin Psychopharmacol
    Hong SB et al., 2012, Dopaminergic and noradrenergic gene polymorphisms and response to methylphenidate in korean children with attention-deficit/hyperactivity disorder: is there an interaction?, J Child Adolesc Psychopharmacol
    Gray et al., 2007, Methylphenidate administration to juvenile rats alters brain areas involved in cognition, motivated behaviors, appetite, and stress., J. Neurosci.
    Chuhan et al., 2006, Impairment of single-trial memory formation by oral methylphenidate in the rat., Neurobiol Learn Mem
    Sandoval et al., 2001, Methamphetamine-induced rapid and reversible changes in dopamine transporter function: an in vitro model., J. Neurosci.
    Yang et al., 2004, Association of norepinephrine transporter gene with methylphenidate response., J Am Acad Child Adolesc Psychiatry
    Williard et al., 2007, Methylphenidate and its ethanol transesterification metabolite ethylphenidate: brain disposition, monoamine transporters and motor activity., Behav Pharmacol
    Tilley et al., 2008, The effects of methylphenidate on knockin mice with a methylphenidate-resistant dopamine transporter., J. Pharmacol. Exp. Ther.
    Berridge CW et al., 2006, Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function., Biol Psychiatry
    Markowitz JS et al., 2006, A comprehensive in vitro screening of d-, l-, and dl-threo-methylphenidate: an exploratory study., J Child Adolesc Psychopharmacol
    Dlugos et al., 2009, Further evidence of association between amphetamine response and SLC6A2 gene variants., Psychopharmacology (Berl.)
    Dlugos et al., 2007, Norepinephrine transporter gene variation modulates acute response to D-amphetamine., Biol. Psychiatry
    Burnette et al., 1996, Human norepinephrine transporter kinetics using rotating disk electrode voltammetry., Anal. Chem.
    Larsen MH et al., 2007, Expression of brain derived neurotrophic factor, activity-regulated cytoskeleton protein mRNA, and enhancement of adult hippocampal neurogenesis in rats after sub-chronic and chronic treatment with the triple monoamine re-uptake inhibitor tesofensine., Eur J Pharmacol
    Bryson HM et al., 1996, Amitriptyline. A review of its pharmacological properties and therapeutic use in chronic pain states., Drugs Aging
    Marshe VS et al., 2017, Norepinephrine Transporter Gene Variants and Remission From Depression With Venlafaxine Treatment in Older Adults., Am J Psychiatry
    Van Ameringen et al., 2009, Pharmacotherapy for social anxiety disorder: an update., Isr J Psychiatry Relat Sci
    Westenberg, 2009, Recent advances in understanding and treating social anxiety disorder., CNS Spectr
    Béïque et al., 1998, Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters., Eur. J. Pharmacol.
    Béïque et al., 2000, Effects of sustained administration of the serotonin and norepinephrine reuptake inhibitor venlafaxine: I. in vivo electrophysiological studies in the rat., Neuropharmacology
    Sindrup et al., 2005, Antidepressants in the treatment of neuropathic pain., Basic Clin. Pharmacol. Toxicol.
    Bymaster et al., 2001, Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors., Neuropsychopharmacology
    Rothman et al., 2002, Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brain., Eur. J. Pharmacol.
    Rothman et al., 2006, Therapeutic potential of monoamine transporter substrates., Curr Top Med Chem
    Heusser et al., 2006, Influence of sibutramine treatment on sympathetic vasomotor tone in obese subjects., Clin. Pharmacol. Ther.
    Gomis Barbará, [Pharmacological treatment of obesity]., Rev Med Univ Navarra
    Birkenfeld et al., 2005, Paradoxical effect of sibutramine on autonomic cardiovascular regulation in obese hypertensive patients--sibutramine and blood pressure., Clin. Auton. Res.
    Jordan et al., 2005, Influence of Sibutramine on blood pressure: evidence from placebo-controlled trials., Int J Obes (Lond)
    Birkenfeld et al., 2002, Paradoxical effect of sibutramine on autonomic cardiovascular regulation., Circulation
    Krahn et al., 2001, Narcolepsy and obesity: remission of severe cataplexy with sibutramine., Sleep Med.
    Tziomalos et al., 2009, The use of sibutramine in the management of obesity and related disorders: an update., Vasc Health Risk Manag
    Berke et al., 2000, Medical management of obesity., Am Fam Physician
    Heusser et al., 2007, Sympathetic vasomotor tone determines blood pressure response to long-term sibutramine treatment., J. Clin. Endocrinol. Metab.
    Sharma et al., 2008, Sibutramine: current status as an anti-obesity drug and its future perspectives., Expert Opin Pharmacother
    Markowitz et al., 2008, Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: does chirality matter?, J Clin Psychopharmacol
    Davids et al., 2002, Stereoselective effects of methylphenidate on motor hyperactivity in juvenile rats induced by neonatal 6-hydroxydopamine lesioning., Psychopharmacology (Berl.)
    Ding et al., 1997, Chiral drugs: comparison of the pharmacokinetics of [11C]d-threo and L-threo-methylphenidate in the human and baboon brain., Psychopharmacology (Berl.)
    Wee et al., 2004, Reinforcing effect of pseudoephedrine isomers and the mechanism of action., Eur. J. Pharmacol.
    Foley et al., 2002, Stereospecific inhibition of monoamine uptake transporters by meta-hydroxyephedrine isomers., J Neural Transm (Vienna)
    Paczkowski FA et al., 2007, chi-Conotoxin and tricyclic antidepressant interactions at the norepinephrine transporter define a new transporter model., J Biol Chem
    Weinshenker et al., 2002, Regulation of norepinephrine transporter abundance by catecholamines and desipramine in vivo., Brain Res.
    Bryan-Lluka et al., 2003, chi-Conopeptide MrIA partially overlaps desipramine and cocaine binding sites on the human norepinephrine transporter., J. Biol. Chem.
    Zavosh et al., 1999, Desipramine treatment decreases 3H-nisoxetine binding and norepinephrine transporter mRNA in SK-N-SHSY5Y cells., Brain Res. Bull.
    Zhu et al., 2004, The persistent membrane retention of desipramine causes lasting inhibition of norepinephrine transporter function., Neurochem. Res.
    Ordway et al., 2005, Norepinephrine transporter function and desipramine: residual drug effects versus short-term regulation., J. Neurosci. Methods
    Proietto et al., 2000, Novel anti-obesity drugs., Expert Opin Investig Drugs
    Stephens et al., 2005, Phentermine and anaesthesia., Anaesth Intensive Care
    Samanin et al., 1993, Neurochemical mechanism of action of anorectic drugs., Pharmacol. Toxicol.
    Tzschentke et al., 2007, (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties., J. Pharmacol. Exp. Ther.
    Hunziker et al., 2005, Duloxetine hydrochloride: a new dual-acting medication for the treatment of major depressive disorder., Clin Ther
    Karpa et al., 2002, Duloxetine pharmacology: profile of a dual monoamine modulator., CNS Drug Rev
    Gould et al., 2007, Effect of chronic administration of duloxetine on serotonin and norepinephrine transporter binding sites in rat brain., Biol. Psychiatry
    Trivedi et al., 2008, Clinical evidence for serotonin and norepinephrine reuptake inhibition of duloxetine., Int Clin Psychopharmacol
    van Groeningen et al., 1989, Lack of effectiveness of combined 5-fluorouracil and leucovorin in patients with 5-fluorouracil-resistant advanced colorectal cancer., Eur J Cancer Clin Oncol
    Jost et al., 2004, Duloxetine: mechanism of action at the lower urinary tract and Onuf's nucleus., Clin. Auton. Res.
    Schou et al., 2005, Post-mortem human brain autoradiography of the norepinephrine transporter using (S,S)-[18F]FMeNER-D2., Eur Neuropsychopharmacol
    Vincent et al., 2004, Clinical assessment of norepinephrine transporter blockade through biochemical and pharmacological profiles., Circulation
    Mirza et al., 2007, Serotonin transporter density and anxiolytic-like effects of antidepressants in mice., Prog. Neuropsychopharmacol. Biol. Psychiatry
    Bymaster et al., 2005, The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression., Curr. Pharm. Des.
    Khullar et al., 2010, Mixed incontinence: current evidence and future perspectives., Neurourol. Urodyn.
    Carter et al., 2009, Duloxetine: a review of its use in the treatment of generalized anxiety disorder., CNS Drugs
    Sulzer et al., 2005, Mechanisms of neurotransmitter release by amphetamines: a review., Prog. Neurobiol.
    Fleckenstein et al., 2007, New insights into the mechanism of action of amphetamines., Annu. Rev. Pharmacol. Toxicol.
    Cheetham et al., 1996, [3H]nisoxetine--a radioligand for noradrenaline reuptake sites: correlation with inhibition of [3H]noradrenaline uptake and effect of DSP-4 lesioning and antidepressant treatments., Neuropharmacology
    Davis et al., 1997, Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression., Drugs
    Taylor et al., 1995, Pharmacology and neurochemistry of nefazodone, a novel antidepressant drug., J Clin Psychiatry
    Owen et al., 1999, Norepinephrine transporter gene polymorphism is not associated with susceptibility to major depression., Psychiatry Res
    Owens et al., 1995, The serotonergic antidepressant nefazodone inhibits the serotonin transporter: in vivo and ex vivo studies., Life Sci.
    Baladi MG et al., 2018, Characterization of the Neurochemical and Behavioral Effects of Solriamfetol (JZP-110), a Selective Dopamine and Norepinephrine Reuptake Inhibitor., J Pharmacol Exp Ther
    Stahl, 2008, Selective histamine H1 antagonism: novel hypnotic and pharmacologic actions challenge classical notions of antihistamines., CNS Spectr
    Leo et al., 2006, Clinical potential of milnacipran, a serotonin and norepinephrine reuptake inhibitor, in pain., Curr Opin Investig Drugs
    Moret et al., 1985, Biochemical profile of midalcipran (F 2207), 1-phenyl-1-diethyl-aminocarbonyl-2-aminomethyl-cyclopropane (Z) hydrochloride, a potential fourth generation antidepressant drug., Neuropharmacology
    Timple JM et al., 2013, The lignan (-)-hinokinin displays modulatory effects on human monoamine and GABA transporter activities., J Nat Prod
    Hampel T et al., 2014, Synthesis and biological effects of new hybrid compounds composed of benzylguanidines and the alkylating group of busulfan on neuroblastoma cells., Bioorg Med Chem Lett
  • DEXMETHYLPHENIDATE   SLC6A2

    Interaction Score: 8.72

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name Focalin
    Novel drug target Established target

    PMIDs:
    17611273 18480678 9537821 16246598 11160413 11862378 15322419 17218796 9181638 18698001


    Sources:
    TdgClinicalTrial

  • ATOMOXETINE   SLC6A2

    Interaction Score: 8.46

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name atomoxetine hydrochloride,Strattera
    Novel drug target Established target

    PMIDs:
    19445548 12456942 12547466 12523874 12862507 9537821 15801334 14709944 16142049 18033153 23266789 19387424 26859445


    Sources:
    TdgClinicalTrial TEND PharmGKB

  • GUANETHIDINE   SLC6A2

    Interaction Score: 7.93

    Interaction Types & Directionality:
    inducer (activating)

    Interaction Info:
    Novel drug target Established target
    Trial Name -

    PMIDs:
    8710929 11403930 16126010


    Sources:
    TdgClinicalTrial TEND

  • PHENMETRAZINE   SLC6A2

    Interaction Score: 4.76

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    12106802 17016423 17139284 17017961


    Sources:
    TdgClinicalTrial TEND

  • SIBUTRAMINE   SLC6A2

    Interaction Score: 4.12

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name sibutramine HCl monohydrate,Meridia, Reductil, Reduxade, Zelium

    PMIDs:
    16678551 15382615 15944869 15685250 12417543 11152984 11752352 19475780 10929704 17284621 18671470


    Sources:
    TdgClinicalTrial TEND

  • DIETHYLPROPION   SLC6A2

    Interaction Score: 3.96

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    19897080 17016423 17139284


    Sources:
    TdgClinicalTrial TEND

  • PHENTERMINE   SLC6A2

    Interaction Score: 2.77

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name -

    PMIDs:
    11060745 16119498 17016423 17139284 7902561


    Sources:
    TdgClinicalTrial TEND

  • DESVENLAFAXINE   SLC6A2

    Interaction Score: 2.54

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name Pristiq

    PMIDs:
    19919295 20944767 19698900 17673606 16675639 19086875


    Sources:
    TdgClinicalTrial TEND

  • SOLRIAMFETOL   SLC6A2

    Interaction Score: 1.59

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name YKP-10A
    Novel drug target Established target

    PMIDs:
    29891587


    Sources:
    TdgClinicalTrial

  • DULOXETINE   SLC6A2

    Interaction Score: 1.59

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name Cymbalta
    Novel drug target Established target

    PMIDs:
    16199241 12481192 16650830 18408530 2784100 14744476 15316838 16139169 15184278 17335951 11752352 15892657 20432324 19480470 9669506


    Sources:
    TdgClinicalTrial TEND

  • PROTRIPTYLINE   SLC6A2

    Interaction Score: 1.36

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    8684598 17016423 17139284 9537821


    Sources:
    TdgClinicalTrial TEND

  • TRIMIPRAMINE   SLC6A2

    Interaction Score: 1.36

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    17016423 17139284 9537821 21484238


    Sources:
    TdgClinicalTrial TEND

  • MILNACIPRAN   SLC6A2

    Interaction Score: 1.27

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name Milnacipran
    Novel drug target Established target

    PMIDs:
    16869117 3005901


    Sources:
    TdgClinicalTrial TEND

  • DESIPRAMINE   SLC6A2

    Interaction Score: 1.27

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    17428804 12137927 12837768 10424850 15002740 9537821 11752352 15814154


    Sources:
    DTC TdgClinicalTrial TEND PharmGKB

  • VENLAFAXINE   SLC6A2

    Interaction Score: 1.27

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name Effexor
    Novel drug target Established target

    PMIDs:
    28068779 19728573 16893531 14744476 19238127 9669506 10884561 15910402 11750180


    Sources:
    TdgClinicalTrial TEND PharmGKB

  • NORTRIPTYLINE   SLC6A2

    Interaction Score: 1.15

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name CRx-170
    Novel drug target Established target
    Trial Name CRx-191

    PMIDs:
    8863842 11502876 9537821 11092898 14744476 17018806


    Sources:
    TdgClinicalTrial TEND

  • NEFAZODONE   SLC6A2

    Interaction Score: 1.11

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    9098663 9537821 7649970 10512149 7475971


    Sources:
    TdgClinicalTrial TEND

  • HINOKININ   SLC6A2

    Interaction Score: 1.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24112084


    Sources:
    DTC

  • TESOFENSINE   SLC6A2

    Interaction Score: 1.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Novel drug target Established target
    Trial Name tesofensine, NS-2330

    PMIDs:
    17112503


    Sources:
    TdgClinicalTrial

  • DEXTROAMPHETAMINE   SLC6A2

    Interaction Score: 1.06

    Interaction Types & Directionality:
    negative modulator (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name SLI 381, SPD 465,Adderall, Adderall XR, Adderall IR

    PMIDs:
    19727679 17239355 8794928


    Sources:
    TdgClinicalTrial

  • IMIPRAMINE   SLC6A2

    Interaction Score: 1.01

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name -

    PMIDs:
    11356924 10193665 14716684 16554743 16893531


    Sources:
    TdgClinicalTrial TEND

  • MAPROTILINE   SLC6A2

    Interaction Score: 1.01

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    17068778 12573515 20141432 17984940 15378668


    Sources:
    TdgClinicalTrial TEND

  • IOBENGUANE   SLC6A2

    Interaction Score: 0.79

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24814532


    Sources:
    DTC

  • LEVOMILNACIPRAN   SLC6A2

    Interaction Score: 0.79

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name levomilnacipran, F2695
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial

  • EDIVOXETINE   SLC6A2

    Interaction Score: 0.79

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Novel drug target Established target
    Trial Name LY-2216684

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial

  • BUPROPION   SLC6A2

    Interaction Score: 0.75

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name BVF-033,Aplenzin
    Novel drug target Established target
    Trial Name Contrave

    PMIDs:
    15361919 12909199 16893531 11752352 28220701 16923164


    Sources:
    TdgClinicalTrial TEND

  • TAPENTADOL   SLC6A2

    Interaction Score: 0.63

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name tapentadol
    Novel drug target Established target

    PMIDs:
    17656655


    Sources:
    TdgClinicalTrial

  • TRAMADOL   SLC6A2

    Interaction Score: 0.62

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name PTI-601
    Novel drug target Established target
    Trial Name tramadol extended-release,Raliva ER

    PMIDs:
    11916794 8955860 19341511 11752352 31004280


    Sources:
    TdgClinicalTrial TEND

  • AMITRIPTYLINE   SLC6A2

    Interaction Score: 0.61

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name OMS-103HP
    Novel drug target Established target
    Trial Name amitriptyline + ketamine,Epicept NP-1

    PMIDs:
    14744476 9537821 8736630


    Sources:
    TdgClinicalTrial TEND

  • AMOXAPINE   SLC6A2

    Interaction Score: 0.57

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name CRx-119
    Novel drug target Established target
    Trial Name CRx-150, amoxapine plus dipyridamole

    PMIDs:
    17016423 17139284 9537821


    Sources:
    TdgClinicalTrial TEND

  • METHYLPHENIDATE   SLC6A2

    Interaction Score: 0.56

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name methylphenidate HCl,Ritalin LA
    Trial Name methylphenidate HCl,Metadate CD, Equasym
    Novel drug target Established target

    PMIDs:
    29374517 29230023 23609393 23083021 17611273 9537821 16246598 11160413 15322419 17218796 18698001 16806100 17201613


    Sources:
    TdgClinicalTrial TEND PharmGKB

  • CLOMIPRAMINE   SLC6A2

    Interaction Score: 0.53

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    9537821 11341486


    Sources:
    TdgClinicalTrial TEND

  • COCAINE   SLC6A2

    Interaction Score: 0.45

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    15113605 15351386 9387868 7500004


    Sources:
    TdgClinicalTrial TEND

  • BETHANIDINE   SLC6A2

    Interaction Score: 0.4

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial TEND

  • DOXEPIN   SLC6A2

    Interaction Score: 0.35

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name doxepin nasal solution,Dolorac
    Novel drug target Established target
    Trial Name Silenor (SO-101)

    PMIDs:
    19179941 9537821


    Sources:
    TdgClinicalTrial TEND

  • PSEUDOEPHEDRINE   SLC6A2

    Interaction Score: 0.28

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name fexofenadine + ps/
    Novel drug target Established target

    PMIDs:
    15189772 12373557


    Sources:
    TdgClinicalTrial

  • METHAMPHETAMINE   SLC6A2

    Interaction Score: 0.18

    Interaction Types & Directionality:
    negative modulator (inhibitory)

    Interaction Info:
    Trial Name low dose intravenous methamphetamine
    Novel drug target Established target

    PMIDs:
    15955613 17209801


    Sources:
    TdgClinicalTrial

  • TEDATIOXETINE   SLC6A2

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name Lu AA24530
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial

  • TRAZODONE   SLC6A2

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TEND

  • Ensembl: ENSG00000103546

    • Version: 101_38

    Alternate Names:
    SLC6A2 Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • TdgClinicalTrial: P23975

    • Version: January-2014

    Alternate Names:
    SLC6A2 Gene Symbol
    SLCA2 Gene Symbol

    Gene Info:
    Target Class Transporters
    Target Subclass TC:2.A.22.1.2

    Publications:

  • RussLampel: ENSG00000103546

    • Version: 26-July-2011

    Alternate Names:
    SODIUM-DEPENDENT NORADRENALINE TRANSPORTER (NOREPINEPHRINE TRANSPORTER) (NET). [SOURCE:UNIPROT/SWISSPROT;ACC:P23975] Description
    ENSG00000103546 Ensembl Gene Id
    SLC6A2 Display Id

    Gene Info:
    Human Readable Name DRUGGABLE GENOME

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • HopkinsGroom: P23975

    • Version: 11-September-2012

    Alternate Names:
    6530 Entrez Gene Id
    SC6A2_HUMAN Uniprot Id
    SLC6A2 Uniprot Gene Name

    Gene Info:
    Interpro Short Name Na/ntran_symport
    Human Readable Name DRUGGABLE GENOME
    Interpro Acc IPR000175

    Gene Categories:
    TRANSPORTER, DRUGGABLE GENOME

    Publications:

  • TEND: P23975

    • Version: 01-August-2011

    Alternate Names:
    6530 Entrez Gene Id
    SLC6A2 Gene Symbol
    P23975 Uniprot Accession

    Gene Info:
    Target Subclass Other
    Target Subclass SLC
    Target Subclass SLC6

    Publications:

  • PharmGKB: SLC6A2

    • Version: 18-August-2020

    Alternate Names:
    PA310 PharmGKB ID

    Gene Info:

    Publications:
    Ramoz N et al., 2009, A haplotype of the norepinephrine transporter (Net) gene Slc6a2 is associated with clinical response to atomoxetine in attention-deficit hyperactivity disorder (ADHD)., Neuropsychopharmacology
    Yang L et al., 2013, Adrenergic neurotransmitter system transporter and receptor genes associated with atomoxetine response in attention-deficit hyperactivity disorder children., J Neural Transm (Vienna)
    Marshe VS et al., 2017, Norepinephrine Transporter Gene Variants and Remission From Depression With Venlafaxine Treatment in Older Adults., Am J Psychiatry

  • NCI: SLC6A2

    • Version: 14-September-2017

    Alternate Names:

    Gene Info:

    Publications:
    Xiao et al., 1995, Acute administration of alpha-methyl-para-tyrosine alters levels of norepinephrine transporter mRNA in the rat brainstem., Brain Res. Mol. Brain Res.

  • DTC: SLC6A2

    • Version: 02-September-2020

    Alternate Names:

    Gene Info:

    Publications:
    Hampel T et al., 2014, Synthesis and biological effects of new hybrid compounds composed of benzylguanidines and the alkylating group of busulfan on neuroblastoma cells., Bioorg Med Chem Lett
    Paczkowski FA et al., 2007, chi-Conotoxin and tricyclic antidepressant interactions at the norepinephrine transporter define a new transporter model., J Biol Chem
    Timple JM et al., 2013, The lignan (-)-hinokinin displays modulatory effects on human monoamine and GABA transporter activities., J Nat Prod

  • HingoraniCasas: ENSG00000103546

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000103546 Gene Symbol
    SLC6A2 Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • GO: SLC6A2

    • Version: 01-February-2022

    Alternate Names:
    NAT1 GO Gene Synonym
    NET1 GO Gene Synonym
    SLC6A5 GO Gene Synonym

    Gene Info:

    Gene Categories:
    CELL SURFACE

    Publications:

  • Pharos: SLC6A2

    • Version: 01-February-2022

    Alternate Names:
    Sodium-dependent noradrenaline transporter Gene Name
    P23975 UniProt ID

    Gene Info:

    Gene Categories:
    TRANSPORTER

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21